Recordati Industria Chimica e Farmaceutica SpA
MIL:REC
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
44.17
54.5
|
Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one REC stock under the Base Case scenario is 52.94 EUR. Compared to the current market price of 52.1 EUR, Recordati Industria Chimica e Farmaceutica SpA is Undervalued by 2%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Recordati Industria Chimica e Farmaceutica SpA
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for REC cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Economic Moat
Recordati Industria Chimica e Farmaceutica SpA
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Recordati Industria Chimica e Farmaceutica SpA is a well-established pharmaceutical company based in Italy, renowned for its commitment to innovation and high-quality healthcare solutions. Founded in 1926, Recordati has evolved from a small family business into a global player in the pharmaceutical industry, focusing on the development and marketing of specialty pharmaceuticals, particularly for rare diseases and niche therapeutic areas. With a strategic emphasis on expanding its portfolio through research and development as well as targeted acquisitions, the company showcases a strong pipeline of products designed to address unmet medical needs, thus positioning itself as a crucial player i...
Recordati Industria Chimica e Farmaceutica SpA is a well-established pharmaceutical company based in Italy, renowned for its commitment to innovation and high-quality healthcare solutions. Founded in 1926, Recordati has evolved from a small family business into a global player in the pharmaceutical industry, focusing on the development and marketing of specialty pharmaceuticals, particularly for rare diseases and niche therapeutic areas. With a strategic emphasis on expanding its portfolio through research and development as well as targeted acquisitions, the company showcases a strong pipeline of products designed to address unmet medical needs, thus positioning itself as a crucial player in the evolving healthcare landscape.
For investors, Recordati presents a compelling opportunity rooted in its steady growth trajectory and solid fiscal health. The company boasts a diverse revenue stream generated from its proprietary medicines, coupled with a robust international presence that spans over 150 countries. With ongoing efforts to strengthen its research capabilities and expand into emerging markets, Recordati is strategically positioned to capitalize on the rising global demand for specialized healthcare products. Its proven track record of performance, paired with a focus on sustainability and corporate responsibility, further enhances its attractiveness as a long-term investment, aligning well with the values of investors seeking ethical and financially sound opportunities in the pharmaceutical sector.
Recordati Industria Chimica e Farmaceutica SpA is an Italian pharmaceutical company known for its specialization in the development, production, and commercialization of pharmaceutical products. The company's business can be broken down into several core segments:
-
Pharmaceuticals:
- Prescription Medicines: Recordati develops and markets a range of prescription medications, particularly focusing on areas such as cardiology, urology, and central nervous system disorders.
- Rare Diseases: The company has a strong emphasis on rare diseases, providing treatments for conditions that affect a small number of patients but require specialized therapies.
- Generic Medicines: Recordati also produces generic drugs, which offer more affordable options for widely-used medications.
-
Secondary Care:
- Recordati engages in the production and marketing of specialty pharmaceuticals that are often used in hospitals or specialized healthcare settings.
-
Consumer Health:
- This segment includes over-the-counter (OTC) products, health supplements, and other consumer-oriented healthcare products. This part of the business focuses on promoting wellness and preventive healthcare.
-
International Presence:
- Recordati operates in numerous international markets, which allows it to diversify its product offerings and revenue streams across various regions, adapting to local healthcare needs and regulations.
-
Research and Development (R&D):
- The company invests in R&D to innovate and improve existing drug formulations, as well as to develop new drugs, particularly in therapeutic areas such as oncology, neurology, and infectious diseases.
Overall, Recordati's business strategy is characterized by a strong focus on niche markets, particularly in the area of rare diseases, alongside a commitment to high-quality pharmaceuticals and consumer health products. Their diversified portfolio allows them to mitigate risks associated with reliance on a singular product or market segment.
Recordati Industria Chimica e Farmaceutica SpA, a global pharmaceutical company, possesses several unique competitive advantages that set it apart from its rivals:
-
Specialization in Rare Diseases: Recordati has a strong focus on developing therapies for rare diseases, an area that often sees less competition but can yield high margins due to limited treatment options. This specialization allows them to build expertise and brand loyalty within niche markets.
-
Established Brand and Reputation: With a robust history spanning over 90 years, Recordati has established itself as a trusted name in the pharmaceutical industry. This reputation can attract partnerships, licensing agreements, and customer loyalty.
-
Diverse Product Portfolio: Recordati has a wide range of products covering various therapeutic areas, including urology, cardiology, and rare diseases. This diversification can mitigate risks associated with market fluctuations in specific segments.
-
Strong Research and Development Capabilities: Ongoing investment in R&D enables Recordati to innovate and bring new products to market. Their expertise in formulating medicines tailored to specific needs is a key advantage over competitors who may have a more generalized focus.
-
Strategic Acquisitions and Partnerships: Recordati has a history of strategic acquisitions that enhance its product offerings and market presence. These partnerships often lead to faster market access for new therapies and broaden their customer base.
-
Global Distribution and Presence: With operations in over 150 countries, Recordati has a well-established global distribution network. This extensive reach enables them to tap into emerging markets and ensure product availability worldwide.
-
Focus on Sustainability and Corporate Responsibility: An increasing number of consumers and stakeholders value sustainability. Recordati's commitment to responsible practices can differentiate it from competitors that may not prioritize environmental, social, and governance (ESG) issues.
-
Adaptability and Market Responsiveness: The company's ability to quickly adapt to changing market dynamics and regulatory environments allows it to seize opportunities and mitigate risks more effectively than some of its larger competitors.
-
Strong Financial Position: A solid financial foundation enables Recordati to invest in growth opportunities, including R&D, marketing, and acquisitions, further strengthening its competitive position.
By leveraging these advantages, Recordati is well-positioned to maintain its competitiveness in the pharmaceutical industry.
Recordati Industria Chimica e Farmaceutica SpA, like any major pharmaceutical company, faces several risks and challenges that may impact its business operations and financial performance in the near future. Here are some of the key risks and challenges that may affect the company:
-
Regulatory Compliance: The pharmaceutical industry is heavily regulated, and compliance with various regulations and guidelines from health authorities across different countries can be complex. Changes in regulations or non-compliance could lead to substantial fines, delays in product launches, or withdrawal of existing products.
-
Intellectual Property Risks: The loss of patent protection for key drugs can result in increased competition from generic manufacturers. Protecting intellectual property and successfully navigating patent litigation challenges is crucial for maintaining market share and revenue.
-
Research and Development (R&D) Risks: Pharmaceutical companies invest heavily in R&D, which is inherently risky. Failures in clinical trials or the inability to bring new drugs to market can significantly affect the company’s growth prospects. Moreover, the increasing costs and time associated with drug development can strain resources.
-
Market Competition: The pharmaceutical market is highly competitive, with many players vying for market share. Recordati must continuously innovate and differentiate its products to stay ahead of competitors, which may require significant investment.
-
Supply Chain Disruptions: Global events, such as pandemics or geopolitical tensions, can lead to disruptions in the supply chain, affecting the production and distribution of pharmaceutical products. This can impact revenue and market availability.
-
Pricing Pressures: There is ongoing pressure from governments, insurers, and healthcare providers to reduce drug prices. This can impact profit margins, particularly for key products. Additionally, pricing strategies may vary significantly across different markets.
-
Market Access and Reimbursement: Gaining market access and securing favorable reimbursement rates for new drugs can be challenging, especially in an environment where healthcare budgets are under pressure. Ineffective market access strategies can limit product uptake and profitability.
-
Evolving Consumer Preferences: Changes in consumer preferences and increased demand for personalized medicine and digital health solutions require pharmaceutical companies to adapt their strategies and offerings quickly.
-
Economic Factors: Economic downturns can influence spending on healthcare and pharmaceuticals. Companies may face challenges in maintaining sales in a recessionary environment, especially for non-essential medications.
-
Strategic Alliances and Acquisitions: Recordati may pursue partnerships or acquisitions to enhance its portfolio, but integrating new businesses and managing relationships can be fraught with risk. Failure to achieve strategic objectives from such ventures can lead to financial losses.
In summary, while Recordati Industria Chimica e Farmaceutica SpA has significant growth potential, it must navigate a complex landscape of regulatory, competitive, and economic challenges to sustain its success in the pharmaceutical industry.
Revenue & Expenses Breakdown
Recordati Industria Chimica e Farmaceutica SpA
Balance Sheet Decomposition
Recordati Industria Chimica e Farmaceutica SpA
Current Assets | 1.2B |
Cash & Short-Term Investments | 200.6m |
Receivables | 592.2m |
Other Current Assets | 452.2m |
Non-Current Assets | 3B |
Long-Term Investments | 20.8m |
PP&E | 183m |
Intangibles | 2.6B |
Other Non-Current Assets | 104.2m |
Current Liabilities | 887.2m |
Accounts Payable | 263.6m |
Short-Term Debt | 50.3m |
Other Current Liabilities | 573.3m |
Non-Current Liabilities | 1.5B |
Long-Term Debt | 1.4B |
Other Non-Current Liabilities | 156.5m |
Earnings Waterfall
Recordati Industria Chimica e Farmaceutica SpA
Revenue
|
2.2B
EUR
|
Cost of Revenue
|
-731.6m
EUR
|
Gross Profit
|
1.5B
EUR
|
Operating Expenses
|
-895.9m
EUR
|
Operating Income
|
596.2m
EUR
|
Other Expenses
|
-209.1m
EUR
|
Net Income
|
387m
EUR
|
Free Cash Flow Analysis
Recordati Industria Chimica e Farmaceutica SpA
EUR | |
Free Cash Flow | EUR |
Recordati reported net revenue of EUR 607 million for Q1 2024, a 10.2% increase year-over-year, bolstered by double-digit growth in both Specialty & Primary Care (SPC) and Rare Disease segments. Despite adverse FX impacts, the company achieved an EBITDA margin of 40.2%. Adjusted net income rose 5.6% to EUR 163.7 million, with free cash flow at EUR 147.1 million. Significant progress was made in R&D, with key drug applications in the pipeline. The company is on track to reach the upper half of its financial targets for 2024 and maintains a positive outlook for 2025.
What is Earnings Call?
REC Profitability Score
Profitability Due Diligence
Recordati Industria Chimica e Farmaceutica SpA's profitability score is 65/100. The higher the profitability score, the more profitable the company is.
Score
Recordati Industria Chimica e Farmaceutica SpA's profitability score is 65/100. The higher the profitability score, the more profitable the company is.
REC Solvency Score
Solvency Due Diligence
Recordati Industria Chimica e Farmaceutica SpA's solvency score is 51/100. The higher the solvency score, the more solvent the company is.
Score
Recordati Industria Chimica e Farmaceutica SpA's solvency score is 51/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
REC Price Targets Summary
Recordati Industria Chimica e Farmaceutica SpA
According to Wall Street analysts, the average 1-year price target for REC is 55.95 EUR with a low forecast of 48.48 EUR and a high forecast of 66.15 EUR.
Dividends
Current shareholder yield for REC is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Recordati SpA engages in the research, development, manufacturing, and marketing of pharmaceuticals. The company is headquartered in Milan, Milano and currently employs 4,303 full-time employees. The company promotes a wide range of pharmaceuticals, both proprietary and under license, in a number of therapeutic areas, such as Antibiotics and Antiviral, Cardiovascular, Central nervous system, Dermatological, Gastroenterology, Genital-urinary system, Muscular-skeletal disorders and pain therapy, Obstetrics and Gynecology and over the counter (OTC) pharmaceuticals. The firm is engaged in the research and development of new drug entities within the cardiovascular and urogenital therapeutic areas and of treatments for rare diseases. It’s product is ZANIDIP, a latest generation calcium-channel blocker for the treatment hypertension. The company operates through Italchimici SpA, Pro Farma AG and North American marketing rights to Cystadane. The firm owns and operates through Natural Point srl also in the food supplement sector.
Officers
The intrinsic value of one REC stock under the Base Case scenario is 52.94 EUR.
Compared to the current market price of 52.1 EUR, Recordati Industria Chimica e Farmaceutica SpA is Undervalued by 2%.